The Oct-3/4 transcription factor sustains embryonic stem (ES) cell self-renewal and is a dose-dependent cell fate determinant. In the adult male, its expression is restricted to type A spermatogonia. We show that Oct-3/4 is expressed in all human testicular germ cell tumors (GCTs) tested, even in the early premalignant component. We demonstrate that Oct-3/4 dictates ES cells' oncogenic potential in a dose-dependent manner; high levels increase the malignant potential of ES cell-derived tumors while Oct-3/4 inactivation induces regression of the malignant component. Oct-3/4 expression in a heterologous cell system transforms nontumorigenic cells and endows tumorigenicity in nude mice. Our findings suggest that Oct-3/4 is not only a distinctive immunohistochemical marker for GCTs, but also plays a critical role in the genesis of these tumors.
Introduction
changes in the chromatin structure in the immediate upstream regulatory region (Ben-Shushan et al., 1993) . In the embryo, Oct-3/4 expression is downregulated in trophoectoderm cells Testicular germ cell tumors (TGCTs) are the most common malignancy in young adult Caucasian males and are responsible and becomes restricted to cells of the inner cell mass of the blastocyst (Palmieri et al., 1994) . From 8.5 days postcoitum for 1 in 7 deaths in this group (Hellerstedt and Pienta, 2002; Oliver, 1999) . It is generally accepted that most types of TGCTs (dpc), expression cannot be detected in any somatic tissue of the mouse embryo (Palmieri et al., 1994; Yeom et al., 1996) . originate from the premalignant lesion intratubular germ cell neoplasia (ITGCN) (Ulbright, 1993) . However, little is known
We have previously shown that in embryonal cells as well, the Oct-3/4 gene, which is unmethylated in the blastula stage, unabout the genetic and molecular events that contribute to the initiation and progression of this neoplastic process (Looijenga dergoes de novo methylation at 6.5 dpc and remains modified in all adult tissues (Gidekel and Bergman, 2002) . The expression and Oosterhuis, 1999) . Understanding these mechanisms may bring about substantial advancements in understanding the gepattern of Oct-3/4 in embryonic and postnatal life suggests that it plays a role as a "stem cell survival" factor. This is supported netic and environmental factors that predispose men to these tumors, as well as enable the development of targeted treatment by recent findings showing that loss of Oct-3/4 expression results in complete loss of pluripotent stem cells in early embrymodalities aimed at curing or preventing this disease in predisposed individuals.
onic life (Nichols et al., 1998) . Moreover, variations in Oct-3/4 levels alone (regardless of other genes) account for the majority The Oct-3/4 transcription factor plays a pivotal role as a key regulator of pluripotency in the earliest stages of mammalian of failures currently observed for somatic cell cloning (Boiani et al., 2002; Donovan, 2001 ). In the adult male mouse, expression development (Brehm et al., 1998) . It has been shown that a critical amount of Oct-3/4 is required to sustain embryonal stem of Oct-3/4 is restricted to type A spermatogonia-the earliest stage in the spermatocytic ontogeny. It is believed that Oct-3/4 (ES) cell self-renewal, and any up-or downregulation induces divergent cell fates. Lack of expression drives the formation of maintains the pluripotency of spermatogonial stem cells and keeps them in an undifferentiated, self-renewing state (Pesce trophoectoderm, and elevated levels result in differentiation into extra embryonic endoderm and mesoderm (Niwa et al., 2000) . et al., 1998) . It has long been argued that tumors are maintained by a Oct-3/4 expression is downregulated in ES cells that are treated with retinoic acid (RA) (Okamoto et al., 1990; Palmieri et al., population of tumor stem cells (Reya et al., 2001) . Because the ability of Oct-3/4 to maintain the stem cell state of germ cells 1994; Rosner et al., 1990; Scholer et al., 1989 Scholer et al., , 1990 , and this reduction is associated with increased DNA methylation and may be advantageous to cancerous cells, we hypothesized that aberrant Oct-3/4 expression may contribute to the neoplastic process in germ cells. A possible role for Oct-3/4 in germ cell tumor evolvement is supported by several additional lines of evidence. Oct-3/4 was initially identified in embryonal carcinoma (EC) cells and is expressed in all EC cell lines assayed thus far (Rosner et al., 1990) . Moreover, our search of the CGAP database identified Oct-3/4 transcripts in several cDNA libraries prepared from primary GCTs (http://cgap.nci.nih.gov), and a recent study using RT-PCR has shown that Oct-3/4 transcripts are present in human GCTs (Palumbo et al., 2002) . Thus, we studied the possibility that aberrant expression of Oct-3/4 may contribute to the neoplastic process in germ cells.
Results

Overexpression of Oct-3/4 in human germ cell tumors
To study whether the Oct-3/4 protein is expressed in human cancer, we raised antibodies specific for the Oct-3/4 protein.
These antibodies gave a specific nuclear staining pattern in type A spermatogonia cells in human testis ( Figure 1A , arrowheads) and not in either more mature sperm ontogeny or the surrounding normal tissues ( Figure 1A ). Control antibody labeling with preimmune rabbit serum was negative (data not shown).
A variety of human normal tissues and tumor samples (archival preserved primary patient material) were tested for the presence of Oct-3/4 protein using immunohistochemical staining. Oct-3/4 expression was seen in all 45 primary human GCTs tested exhibiting a range of expression levels ( Figure 1 ). The variability observed in Oct-3/4 expression could be due to inherent differences in the tumors or to differences in the preservation of excised material. The GCTs that express Oct-3/4 include embryonal carcinomas ( Figures 1B-1F ), seminomas (Figures 1G ples from 16 lung tumors, 19 colon tumors, 7 stomach tumors, 7 liver tumors (primary hepatocellular carcinoma and metastases to the liver), 15 breast tumors, 14 ovarian tumors, 8 endomeThese tumors are morphologically similar to human immature trial carcinomas, 16 prostate carcinomas, 7 bladder carcinomas, teratomas, a subtype of GCTs, and are characterized by the 7 kidney carcinomas, 7 pancreatic cancers, 11 thyroid tumors, presence of a mixture of mature and immature embryonal tis-14 skin tumors, 14 lymphomas, and 20 brain tumors. The array sues (Ulbright, 1993) . Human immature teratomas are graded slide contained normal testicular tissue as well, which showed into a four tiered system according to the relative abundance positive Oct-3/4 staining and served as a positive control for of primitive neural tissue present. Grade 0 tumors harbor no the experimental procedure (data not shown). Therefore, our immature tissue whereas grade 3 denotes an immature teratoma findings clearly show that Oct-3/4 is specifically expressed in with abundant primitive tissue (Norris et al., 1976) . While grade 0 GCTs.
teratomas are benign lesions with a 5 year survival rate of 100%, grade 3 teratomas are highly malignant tumors with a 5 year Aberrant expression of Oct-3/4 influences survival rate of 33% for tumors that were considered to be the malignant potential of the tumors generated localized on operation (Zalel et al., 1996) . Thus, the prognosis from inoculation of ES cells is directly related to the percentage of immature tissue present It was shown previously that mice injected with either human or murine ES clones develop mixed teratomas (Damjanov, 1987) .
in these tumors. Interestingly, immunohistochemical staining of immature teratomas formed from wild-type (wt) ES cells showed 3/4 transgene. We used two kinds of Ola129/Sv ES cell lines engineered by Niwa and collaborators (Niwa et al., 2000) . Both that while most of the tissue was negative for Oct-3/4 expression, all malignant foci, and some of the areas composed of types of cell lines harbor a tetracycline-inducible Oct-3/4 transgene in which expression is induced after withdrawal of doxycyprimitive brain tissue, were positive for Oct-3/4 expression (Figures 2A and 2B) . Staining of serial sections with an antibody cline (dox). The ZHTc6 and ZHTc25 clones are heterozygous for the endogenous Oct-3/4 gene (Oct-3/4 Ϫ/ϩ ), whereas in the directed against the proliferation marker Ki-67 showed that Oct-3/4-expressing foci are highly proliferative ( Figure 2C ).
ZHBTc4 clone, both Oct-3/4 alleles are disrupted (Oct-3/4 Ϫ/Ϫ ). Upon induction of the inducible transgene in ZHTc6 and ZHTc25 Oct-3/4 expression level was previously shown to be a key factor in determining the cell fate in the early embryo (Niwa et cells, Oct-3/4 levels increase to 150% relative to wt ES cells. ZHBTc4 cells, harboring no functional endogenous Oct-3/4 al., 2000) . To address the possibility that various levels of Oct-3/4 expression may affect the tumorigenic capacity of ES cells, gene, express the inducible transgene at a level of 50% of wt levels, whereas in the presence of dox, these cells do not exwe inoculated mice with ES cells that harbor an inducible Oct- Mice were inoculated with the various clones and followed for tumor development with or without dox, as indicated. The relative Oct-3/4 expression levels are inferred from the in vitro findings (Niwa et al., 2000 press the Oct-3/4 protein at all (Niwa et al., 2000) . Thus, these ing the relative proportion of different components in a sampled tissue (Hammel et al., 1989) . cleverly engineered ES cells that express Oct-3/4 at 0%-150% allowed us to study the effect of different levels of Oct-3/4 on To this end, we found that mice that were inoculated with ZHTc25 cells and given plain drinking water developed tumors the malignant potential of ES cells.
Cells from wt ES, ZHTc6, ZHTc25, and ZHBTc4 clones were that contained a higher proportion of primitive neural tissue compared with tumors from dox-provided mice or with tumors injected subcutaneously into syngeneic Ola129/SV mice. Mice inoculated with the ZHTc25 or ZHTc6 cells were either treated or from mice injected with wt ES cells (35.1% Ϯ 4.3%, n ϭ 5 versus 11.7% Ϯ 3.3%, n ϭ 5 and 15.1% Ϯ 4.3%, n ϭ 4, not with 0.2 mg/ml dox in their drinking water. Tumors became apparent at the site of injection within 2 to 4 weeks in 83% of respectively, p ϭ 0.01, Figure 2H and Table 1 ). In addition, we calculated the percentage of primitive neural cells with regard the mice injected with wt ES. Mice injected with ZHTc25 and treated or not with dox-containing water developed tumors in to the total amount of neural tissue present in the tumor mass. Again, upregulation of Oct-3/4 ( Figure 2 , compare F and G) 70% and 64% of the cases, respectively. In marked contrast, only 40% (p Ͻ 0.01 compared with wt ES) of mice inoculated resulted in a higher percentage of primitive neural tissue in ZHTc25 tumors in the absence of dox (64% Ϯ 5%) versus the with ZHBTc4 and given plain drinking water developed tumors, and this percentage dropped to 4.3% when dox was added to presence of dox (24% Ϯ 7%, p Ͻ 0.01, Figure 2 , compare D and E), or in wt ES tumors (28% Ϯ 4%, p Ͻ 0.02). Similar results the water (p Ͻ 0.0001 compared with wt ES, Table 1 ). This is not a result of decreased proliferative potential since in vitro were obtained with an additional independent clone, ZHTc6 ( Figure 2H ), indicating that this phenotype is a direct result of the proliferation rate of the various clones was found to be similar (data not shown). These results suggest that lower levels upregulation of Oct-3/4 expression. Taken together, we found that upregulating Oct-3/4 levels resulted in a higher proportion of Oct-3/4 expression (below 75%) hinder tumor formation.
To determine the effect of Oct-3/4 overexpression, mice of tumors containing primitive neural and malignant-appearing tissues, compared with tumors having developed either from injected with ZHTc25 cells were divided into groups maintained either on plain water or on water supplemented with dox. These wt ES or from engineered ES cells in which Oct-3/4 levels are kept low ( Figure 2H and Table 1 ). These data bear relevance to animals were sacrificed when the tumors reached the size of 1 cm 2 for histological examination. The tissues were examined the corresponding human tumors since, as noted above, a higher proportion of immature tissue indicates a more malignant for the presence of primitive, mature, and malignant cells. Malignant phenotype is characterized by the appearance of pleomorbehavior in these human tumors.
Mice injected with ZHBTc4 cells, expressing Oct-3/4 from phic and hyperchromatic nuclei and abundant mitoses as evidenced by high power view of the tumors. Primitive brain tissue the transgene only, developed tumors that were enriched for trophoblastic tissue as compared with a very low level of this is characterized by neuropil packed with small neuroblast-like cells with dark nuclei and high mitotic activity, while mature tissue in tumors evolving from injection of ZHTc25 cells (11.2% Ϯ 8.9%, n ϭ 5 versus 0.02% Ϯ 0.03%, n ϭ 5, p Ͻ brain is characterized by less crowding and the appearance of differentiated neurons. Quantitation of these histological analy-0.005, Figures 3A-3C ). It is generally accepted that the different subtypes of GCTs correspond to different lineages or stages in ses were obtained from a systematic sampling analysis of hematoxylin-and eosin-stained sections from all tumors (Hammel et the developing embryo. For instance, seminoma is regarded as a recapitulation of spermatogonia; embryonal carcinoma correal., 1989). Briefly, we randomly sampled ten microscopic fields (1.1 mm ϫ 1.4 mm each) from each tumor for analysis. A matrix sponds to inner cell mass cells and choriocarcinoma to trophoblastic tissues (Chaganti and Houldsworth, 2000) . In accorof 20 ϫ 20 dots was applied to each field, and tissue type for each dot was assigned and recorded. The reader was blinded dance, the malignant component in ZHBTc4-derived tumors, expressing lower levels of Oct-3/4, was mainly composed of to the ES cell clone as well as to the mouse treatment group. Thus, approximately 4,000 different points were analyzed per choriocarcinoma rather than embryonal carcinoma, typically found in tumors derived from ZHTc25 and ZHTc6 cells. As tumor sample. The relative frequency of each tissue type assigned to all dots corresponds to the proportional volume of previously noted, only 1 mouse out of 23 (Table 1) injected with ZHBTc4 cells and fed with dox developed a tumor. This tumor this tissue type in the entire tumor. This labor intensive analysis has previously been shown to be the optimal method for evaluatwas extremely small and composed of mature trophoblast cells with no immature areas (data not shown). Interestingly, our in from the stably integrated dox-regulated transgene since both endogenous Oct-3/4 alleles were disrupted. To address this vivo results clearly corroborate previously published in vitro experiments showing that downregulating Oct-3/4 expression in question, mice were injected with ZHBTc4 cells, kept in the absence of dox and followed for tumor appearance. Once tuZHBTc4 cells results in differentiation toward the trophoblastic lineage (Niwa et al., 2000) . Thus, our data suggest that also in mors reached the size of 1 cm 2 , mice were assigned to either one of two groups: one treated with dox (12 mice) and the other ZHBTc4 cells, upregulating Oct-3/4 expression results in more aggressive tumors, as judged by the abundance of malignant without (11 mice). After three weeks, the tumors were subjected to histological analysis. Several sections were examined from tissue, whereas low levels of Oct-3/4 expression are associated with mature/differentiated tissue. Moreover, these results also each tumor and representative images are shown in Figure 3 . emphasize that Oct-3/4 expression is cardinal for tumor forIn all mice, administration of dox (resulting in downregulation mation since ES cells devoid of Oct-3/4 hardly generated any of Oct-3/4 expression, Figure 3 , compare G to H) was associated tumors.
with tumor regression, as evidenced by histological analysis revealing mature tissue ( Figures 3D-3F ), large areas of fibrosis, granulation tissue, and signs of hemorrhage. Remarkably, in a Expression of Oct-3/4 is required for maintenance of the malignant phenotype subset of these tumors (4/12), complete disappearance of the malignant component was observed following dox addition. ZHBTc4 cells provided us with the opportunity to investigate whether Oct-3/4 expression is required for maintenance of the These findings are in complete contrast with abundant malignant tissue found in all (11/11) mice not treated with dox (Figures immature tumor phenotype. These cells express Oct-3/4 only 3A-3C). Quantitative assessment of the abundance of malignant tissue revealed a 10-fold reduction in the mean percentage of malignant tissue in tumors that grew in the presence of dox compared with the untreated group (1.7% Ϯ 0.1% versus 19% Ϯ 0.9%, respectively, p Ͻ 0.02, Figure 3J ). These results indicate that Oct-3/4 expression is essential for maintenance of these tumors and suggest that Oct-3/4 functions as an oncogene.
Oct-3/4 is a candidate oncogene in Swiss 3T3 cells Several homeobox-containing genes were previously shown to transform nontumorigenic fibroblasts in vitro (Maulbecker and Gruss, 1993; Qin et al., 1994; Stuart et al., 1995; Soubeyran et al., 2001) . We set out to directly test the oncogenic potential of Oct-3/4 in this system as well. Nontumorigenic Swiss 3T3 fibroblast cells were transfected with the Oct-3/4 expression vector (pBL-Oct-3/4-EGFP), the empty vector (pBL-EGFP), and as a positive control the oncogenic ras expression vector (H-rasV12, pBpRas kindly provided by W.C. Hahn). Western blot analysis of nuclear extracts and immunofluoresence staining revealed that all the independent cell lines transfected with pBLOct-3/4-EGFP expressed the Oct-3/4 protein in the nucleus, whereas control cell lines did not ( Figure 4A , showing representative clones). Four independent subclones from each group were assayed for their ability to grow in soft agar. This experiment was performed because loss of anchorage dependence is a hallmark of tumor cells, and the ability to promote anchorageindependent growth is a common property of oncogenes. Swiss 3T3 wt cells, as well as those harboring the pBL-EGFP vector only, did not form colonies whereas ras-expressing cells did. Remarkably, expression of Oct-3/4 stimulates formation of robust colonies in soft agar, with a cloning efficiency similar to oncogenic ras ( Figures 4B-4D and Table 2 ). Moreover, either a point mutation in the DNA binding domain (Vigano and Staudt, 1996) or a deletion in the C-terminal region that harbors the specific transcriptional activation domain (Brehm et al., 1997) completely abrogated the ability of Oct-3/4 to form colonies in soft agar (Table 2 ). These results indicate that Oct-3/4 shares the ability to promote anchorage-independent growth with oncogene products, and both the DNA and the C-terminal transactivation domains play a crucial role in this ability.
To find out whether Swiss 3T3 cells expressing Oct-3/4 are tumorigenic in vivo, cells expressing Oct-3/4, vector only, or of these tumors, the malignant component completely disap- Felsher and Bishop, 1999b; Jain et al., 2002) . Thus, it seems likely that the response of tumors to remediation of a single genetic lesion will vary with the nature of the initiating oncogene and the cellular lineage of the tumors. Our findings showing residual malignant component in the tumor mass in a Discussion subset of the tumors where Oct-3/4 expression was downregulated could result from secondary genetic changes that are In this study, we used ES cell lines with dox-dependent Octresponsible for the transformed phenotype. Alternatively, it is 3/4 expression to investigate whether Oct-3/4 can influence the possible that we did not wait long enough for the disappearance tumorigenic phenotype of ES cells in a dose-dependent manner.
of the entire malignant component.
Mice injected with either ZHTc6 or ZHTc25 cells, overexpressing
Our results, along with a very recent extensive study Oct-3/4, developed tumors with a more primitive and malignant (Looijenga et al., 2003) , show that Oct-3/4 is overexpressed in phenotype as compared with tumors that arose from injection human GCTs, as early as the carcinoma in situ stage all the of the same cells in which Oct-3/4 expression is downregulated.
way through metastatic lesions. Oct-3/4 is normally expressed Oct-3/4 was previously shown to serve as a dose-dependent in the earliest stages of spermatogenesis (Pesce et al., 1998) . cell fate/differentiation determinant. The level of Oct-3/4 expresThus, these results fit well with the growing body of evidence sion dictates the cellular phenotype, with low levels driving difthat links cancer with genes and pathways that are required for ferentiation toward trophoectoderm and high levels resulting in normal embryonic patterning. In many cases, cancer seems to differentiation into mesoderm and primitive endoderm lineages be caused by the deregulation of transcription factors that affect (Niwa et al., 2000) . In this study, we show that in mouse xenocell fate and proliferation. Two well-studied examples are (1) grafts in vivo, Oct-3/4 influences the oncogenic fate in a dosethe wnt pathway, which in normal intestine regulates cell fate dependent manner. ES cells expressing low levels of Oct-3/4, and is involved in colon cancer through aberrant regulation ZHBTc4, gave rise to tumors that were enriched for trophoblast of ␤-catenin (van de Wetering et al., 2002) and (2) the Sonic tissue, whereas mice injected with ES cells containing high hedgehog-Gli signaling pathway, which normally regulates epilevels of Oct-3/4, ZHTc6 and ZHTc25, developed embryonal dermal differentiation and whose inappropriate activation occarcinomas/primitive neural tumors. Moreover, we provide data curs in several types of tumors, including those of brain and to show that expression of Oct-3/4 in a heterologous cell system skin (Dahmane et al., 2001; Grachtchouk et al., 2000 ; Nilsson confers a malignant phenotype upon these cells, evidenced by et al., 2000). Interestingly, both Oct-3/4 and Gli proteins seem colony formation in soft agar, tumorigenicity in nude mice, and to be involved in tumors that are derived from tissues in which the appearance of histological hallmarks of malignancy such as these proteins are active. These findings support the view that marked pleomorphism, invasiveness, and necrosis. This activity many molecular pathways that underlie carcinogenesis reprerequires both the C-terminal and the DNA binding domains. sent aberrations of the normal processes that control emTherefore, our findings that Oct-3/4 confers a malignant phenobryogenesis. type upon Swiss 3T3 cells, increases the malignant potential of An additional example of deregulation of transcription fac-ES cells, and is ubiquitously expressed in all human GCTs from tors that affect cell fate and proliferation are the homeobox the earliest detectable stage highly suggest that aberrant Octgenes, which encode transcription regulatory proteins that are 3/4 expression may play a cardinal role in genesis of GCTs.
widely used during development and are often aberrantly exWe have found that the tumors obtained from injection of pressed in cancer (Abate-Shen, 2002; Stuart et al., 1995) . A ES cells that express Oct-3/4 only from a dox-inducible Oct-3/4 transgene, ZHBTc4, regress after dox addition. In a subset number of these genes were shown to induce transformation feld, 1997; Verrijzer and Van der Vliet, 1993 maintaining the pluripotent phenotype of ES cells and directing differentiation to particular cellular lineages (Niwa et al., 2000) .
Cell culture
It is clear that Oct-3/4 cumulative activities provide a balance
Wild-type CGR8 ES cells, ZHTc25, and ZHBTc4 ES cells were cultured between proliferation and differentiation. Thus, it is reasonable without feeders in LIF-supplemented medium in the presence or absence to suggest that deregulated Oct-3/4 expression distorts the of dox as described previously (Niwa et al., 2000) . Swiss 3T3 cells (Clontech balance toward a transformed phenotype. In this context, it is Laboratories, Palo Alto, California) were maintained in DMEM supplemented interesting to note that expression of the stem cell-specific with 10% fetal calf serum in the presence of G418 (250 g per ml, Invitrogen growth factor fgf-4 (Wilder et al., 1997) , which is one of OctLife Technologies, Carlsbad, California).
3/4's putative target genes, is associated with human testicular as a possible safe target for gene-directed therapy.
Mouse xenograft assay Experimental procedures
Cells were trypsinized and resuspended in PBS. 6 ϫ 10 6 viable wt Swiss 3T3 cells or transfected clones with either pBL-EGFP, pBL-Oct-3/4-EGFP, Clinical samples or pBp-Ras were injected subcutaneously into the left flank of Cd1 nude Forty-five GCTs including embryonal carcinoma, seminoma, and mixed germ cell tumor samples, in addition to 4 non-GCT testicular tumors, were colmice. POUerful marker of the mammalian germline? Apmis 106, 114-124; discusdays with calipers, and animals were sacrificed either when the tumors sion 124-116. reached the size of 1 cm 2 or 12 weeks after injection. Tumors were weighed, fixed in formalin, and embedded in paraffin for immunohistochemical analyChaganti, R.S., and Houldsworth, J. (2000). Genetics and biology of adult sis. For tumor regression experiments, mice were inoculated with 3 ϫ 10 6 human male germ cell tumors. Cancer Res. 60, 1475-1482. ZHBTc4 ES cells, as above, and followed for tumor development. When Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, tumors reached a size of 1 cm 2 , mice were randomly assigned to either one Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) . Essential role for of two groups: one fed with plain water and the other with water suppleoncogenic Ras in tumour maintenance. Nature 400, 468-472. mented with dox. Mice were kept for an additional 2 weeks. Dahmane, N., Sanchez, P., Gitton, Y., Palma, V., Sun, T., Beyna, M., Weiner, Histology, immunohistochemistry, and H., and Ruiz i Altaba, A. (2001) . The Sonic Hedgehog-Gli pathway regulates immunofluorescence staining dorsal brain growth and tumorigenesis. Development 128, 5201-5212. Formalin-fixed, paraffin-embedded xenograft samples were cut into 5 m Damjanov, I. (1987) . Human yolk sac carcinoma antigens-a step beyond sections, deparaffinized in xylene, and rehydrated through a series of dealpha-fetoprotein. Lab. Invest. 57, 347-349. creasing concentrations of ethanol. Sections were stained with hematoxylin and eosin or with the indicated antibodies. For immunofluorescence staining, D'Cruz, C.M., Gunther, E.J., Boxer, R.B., Hartman, J.L., Sintasath, L., Moody, cells (5 ϫ 10 5 ) were allowed to adhere to glass coverslips pretreated with S.E., Cox, J.D., Ha, S.I., Belka, G.K., Golant, A., et al. (2001) . c-MYC induces 0.2% gelatine. Twenty-four hours later, cells were washed with 1ϫ PBS and mammary tumorigenesis by means of a preferred pathway involving spontafixed in 3.7% paraformaldehyde, permeabilized with 0.2% triton x-100, and neous Kras2 mutations. Nat. Med. 7, 235-239. blocked with 1% BSA. The slides were incubated with antibody against the Donovan, P.J. (2001). High Oct-ane fuel powers the stem cell. Nat. Genet. mouse Oct-3/4 protein for 40 min at 25Њc and than washed with PBS.
29, 246-247. Secondary antibody conjugated to FITC (Jackson Immunoresearch Laboratory Inc., West Grove, Pennsylvania) was then used to detect Oct-3/4 immuEwald, D., Li, M., Efrat, S., Auer, G., Wall, R.J., Furth, P.A., and Hennighausen, noreactivity. The slides were examined and photographed.
L. (1996) . Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen. Science 273, 1384-1386.
